Latest News and Press Releases

Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung...

ENSPRYNG® ist das erste und einzige in der Schweiz zugelassene Medikament zur Behandlung von Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) bei Patienten die Antikörper gegen Aquaporin 4...

ENSPRYNG® est le premier et le seul médicament homologué en Suisse pour le traitement des Troubles du Spectre de la Neuromyélite Optique (NMOSD) chez les patients porteurs d’anticorps contre...

Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified1,2,3 STASEY is the largest...

Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel...

Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administration Data showed that 85% of patients preferred...

Spark Therapeutics will present data from the initial dose cohorts of its phase I/II SPK-8011 gene therapy study, showing stable and durable factor VIII expression, substantial improvement in...

ENSPRYNG is Japan’s first and only approved therapy for both adults and children with neuromyelitis optica spectrum disorder (NMOSD) ENSPRYNG is the first and only approved therapy targeting the...

uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining positivityRoche advances...

      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone...